Skip to main
  1. Stocks
  2. Cardiff Oncology
  3. Forecast
CRDF

Cardiff Oncology (CRDF) Stock Forecast & Price Target

Cardiff Oncology (CRDF) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Cardiff Oncology is viewed positively because it has resolved all outstanding litigation with Nerviano, strengthening control over onvansertib’s global rights and reducing strategic uncertainty around its lead PLK1 inhibitor. The amended agreement also preserves exclusivity, adds revised economics tied to future sales and development milestones, and aligns governance as the company advances its Phase 3 program. Fundamentally, the investment case is reinforced by CRDF-004 data showing a 72.2% ORR versus 42.1% in control and median PFS not reached versus about 11 months, alongside a manageable safety profile in first-line RAS-mutated mCRC.

Bears say

Cardiff Oncology is facing a material legal and operational overhang after Nerviano Medical Sciences notified it on May 27, 2026 of termination of the onvansertib license, alleging material breach tied to inventorship correction and insufficient commercially reasonable development efforts. This dispute threatens control over the company’s main clinical asset, including regulatory communications, development data, and ongoing trial oversight, which could disrupt the Phase 2 program in first-line RAS-mutated metastatic colorectal cancer and weaken confidence in the broader PLK1 strategy. With unresolved litigation in Case No. 3:26-cv-3131-RBM-JLB and repeated termination threats from Nerviano since April 20, 2026, the stock faces elevated execution and partnering risk until legal clarity emerges.

Cardiff Oncology (CRDF) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cardiff Oncology and is not a guaranteed prediction by Public.com or investment advice.

Cardiff Oncology (CRDF) Analyst Forecast & Price Prediction

Get the latest Cardiff Oncology (CRDF) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Cardiff Oncology (CRDF)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cardiff Oncology (CRDF) Forecast

Analysts have given Cardiff Oncology (CRDF) a Buy based on their latest research and market trends.

According to 3 analysts, Cardiff Oncology (CRDF) has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cardiff Oncology (CRDF)


Cardiff Oncology (CRDF) Analyst Forecast & Price Prediction

Get the latest Cardiff Oncology (CRDF) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Cardiff Oncology (CRDF)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CRDF stock data and trends